Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PIERRE GHOLAM

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1477579647
CMS profile
490846
Location
CLEVELAND, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$112,815.59

138 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Eisai Inc. $24,559.64 31
Gilead Sciences, Inc. $17,180.06 25
AbbVie Inc. $16,952.11 24
Exelixis Inc. $13,647.20 9
Shionogi Inc $11,712.70 7
E.R. Squibb & Sons, L.L.C. $10,063.11 6
Intercept Pharmaceuticals, Inc. $7,172.96 10
Genentech USA, Inc. $6,412.95 11
Genentech, Inc. $2,375.00 1
Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,538.53 8
Bayer HealthCare Pharmaceuticals Inc. $1,122.00 1
Janssen Biotech, Inc. $43.78 3
IRONWOOD PHARMACEUTICALS, INC $35.55 2

Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PIERRE GHOLAM

NPI 1477579647 · CMS profile ID 490846

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

CLEVELAND, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1477579647?year=2020&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PIERRE GHOLAM, NPI 1477579647, CMS profile ID 490846. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1477579647?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). PIERRE GHOLAM, NPI 1477579647, CMS profile ID 490846. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1477579647?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
PIERRE GHOLAM, NPI 1477579647, CMS profile ID 490846, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1477579647?year=2020&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

138 matching records · $112,815.59 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 138 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–138 of 138.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Shionogi Inc $42.9502/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750203149 CMS
Genentech USA, Inc. $24.2002/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743082325 CMS
E.R. Squibb & Sons, L.L.C. $120.3502/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728007815 CMS
Intercept Pharmaceuticals, Inc. $16.8702/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739850147 CMS
E.R. Squibb & Sons, L.L.C. $4,125.0001/31/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728007797 CMS
AbbVie Inc. $8.6401/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721816517 CMS
Shionogi Inc $17.6101/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750203099 CMS
Exelixis Inc. $21.2301/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737178837 CMS
Exelixis Inc. $5,180.0001/27/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737178839 CMS
Exelixis Inc. $219.0201/27/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737178841 CMS
Exelixis Inc. $44.1501/27/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737178843 CMS
Exelixis Inc. $774.7001/27/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737178845 CMS
Exelixis Inc. $28.1001/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737178847 CMS
Eisai Inc. $2,160.0001/25/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751339391 CMS
Eisai Inc. $120.3701/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751339465 CMS
Eisai Inc. $397.1401/25/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751339467 CMS
Genentech USA, Inc. $136.3501/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743082339 CMS
E.R. Squibb & Sons, L.L.C. $107.7601/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728007795 CMS
Genentech USA, Inc. $339.8401/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743082365 CMS
Genentech USA, Inc. $145.0101/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743082345 CMS
Genentech USA, Inc. $3,000.0001/21/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743082349 CMS
Genentech USA, Inc. $418.0701/21/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743082357 CMS
Genentech USA, Inc. $402.4101/21/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743082371 CMS
Genentech USA, Inc. $73.0501/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743082377 CMS
Genentech USA, Inc. $40.0001/21/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743082381 CMS
Genentech USA, Inc. $84.0201/21/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743082389 CMS
Eisai Inc. $3,150.0001/14/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751342879 CMS
Eisai Inc. $1,000.0001/14/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751342881 CMS
Eisai Inc. $582.6001/14/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751342883 CMS
Eisai Inc. $309.6901/14/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751342885 CMS
Eisai Inc. $23.1801/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751342887 CMS
Eisai Inc. $24.1501/14/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751342889 CMS
Eisai Inc. $20.0001/14/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751342891 CMS
Eisai Inc. $112.2601/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751342893 CMS
Eisai Inc. $750.7301/14/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751346917 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $27.2901/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737530305 CMS
AbbVie Inc. $16.7801/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721816513 CMS
Intercept Pharmaceuticals, Inc. $12.4601/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739850145 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $267,766.21 342
PY2020 $112,815.59 138
PY2021 $133,254.65 150
PY2022 $179,436.77 230
PY2023 $221,256.83 269
PY2024 $232,655.62 255
PY2025 $459,055.31 414

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $60,225.75 15
PY2023 Principal investigator $72,270.30 18
PY2022 Recipient $121.01 2
PY2022 Principal investigator $33,735.80 12
PY2021 Principal investigator $32,577.90 10
PY2020 Principal investigator $33,497.10 16
PY2019 Principal investigator $101,304.02 24

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

15 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Bausch Health US, LLC $1,500.00 05/06/2024 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospital
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151651188
Principal investigator 1 Intercept Pharma Europe Ltd. $9,775.75 03/27/2024 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospital
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 1119227729
Principal investigator 1 Intercept Pharma Europe Ltd. $17,350.00 03/14/2024 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospital
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 1119227723
Principal investigator 1 Intercept Pharma Europe Ltd. $500.00 03/14/2024 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospital
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 1119227725
Principal investigator 1 Intercept Pharma Europe Ltd. $3,300.00 03/14/2024 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospital
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 1119227727
Principal investigator 1 Bausch Health US, LLC $1,650.00 02/22/2024 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospital
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151651192
Principal investigator 1 Bausch Health US, LLC $1,000.00 02/22/2024 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospital
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151651197
Principal investigator 1 Bausch Health US, LLC $2,000.00 02/22/2024 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospital
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151651201
Principal investigator 1 Bausch Health US, LLC $800.00 02/22/2024 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospital
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151651206
Principal investigator 1 Bausch Health US, LLC $15,000.00 02/22/2024 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospital
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151651210
Principal investigator 1 Bausch Health US, LLC $2,000.00 02/22/2024 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospital
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151651215
Principal investigator 1 Bausch Health US, LLC $1,050.00 02/22/2024 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospital
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151651219
Principal investigator 1 Bausch Health US, LLC $1,500.00 02/22/2024 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospital
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151651223
Principal investigator 1 Bausch Health US, LLC $2,000.00 02/22/2024 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospital
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151651228
Principal investigator 1 Bausch Health US, LLC $800.00 02/22/2024 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospital
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151651232